Side effect caused by the new immunotheraphies: Hypopigmented Skin Lesions

New immunotherapies such as immune checkpoint inhibitors: anti-CTLA4, anti–PD-1 and anti-PD-L1 monoclonal antibodies are emerging as standard treatments in various malignant diseases.

The list of current indications is likely to expand as these immunotherapies are tested with promising results in many cancer types. Immunotherapies have a unique pattern of toxic effects similar to autoimmune symptoms called immune-related adverse events (irAEs).Vitiligo is an acquired pigmentary disorder characterized by hypopigmented macules caused by autoimmune destruction of melanocytes. In patients with melanoma, vitiligo-like symptoms can occur as an irAE in between 3.4% and 25% of patients during treatment with an immune checkpoint inhibitor